Table 1.
All patients (n=293) |
Depressed/anxious (n=81) |
Not depressed/anxious (n=212) |
p Value | |
---|---|---|---|---|
Age, mean (SD) | 57 (15) | 54 (15) | 58 (14) | 0.02 |
Female, n (%) | 193 (66) | 58 (72) | 135 (64) | 0.20 |
Symptom duration in months, median (IQR) | 3 (1-8) | 3 (1-7) | 3 (1-8) | 0.72 |
Currently smoking, n (%) | 65 (23) | 25 (33) | 40 (20) | 0.08 |
ACPA positive, n (%) | 162 (55) | 43 (53) | 119 (56) | 0.64 |
ESR (mm/h) median (IQR) | 28 (14-41) | 28 (14-42) | 28 (14-41) | 0.85 |
CRP (mg/L), median (IQR) | 10 (3-22) | 7 (3-26) | 10 (3-20) | 0.76 |
EGA, mean (SD) | 49 (20) | 49 (24) | 49 (19) | 0.44 |
PGA, mean (SD) | 45 (27) | 54 (27) | 42 (26) | 0.001 |
Pain, mean (SD) | 60 (25) | 63 (24) | 58 (25) | 0.92 |
68-TJC, median (IQR) | 10 (5-17) | 11 (6-19) | 10 (5-16) | 0.18 |
66-SJC, median (IQR) | 5 (2-11) | 5 (2-10) | 6 (2-11) | 0.14 |
DAS44, mean (SD) | 2.9 (0.8) | 3.0 (0.8) | 2.9 (0.8) | 0.45 |
Pain measured by a 0-100 Visual Analogue Scale (VAS); ACPA, anti-citrullinated peptide antibody; 68-TJC, 68 tender joint counts; 66-SJC, 66 swollen joint counts; EGA, evaluator’s global assessment by a 0-100 VAS; PGA, patient’s global assessment by a 0-100 VAS; 44-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; CRP, c-reactive protein; SD, standard deviation; IQR, Inter quartile range.